Hepatic Safety and Tolerability of Raltegravir among HIV Patients Coinfected with Hepatitis B And/Or C | Zendy

Christopher B. Hurt | Zendy; Sonia Napravnik | Zendy; Richard D. Moore | Zendy; Joseph J. Eron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hepatic Safety and Tolerability of Raltegravir among HIV Patients Coinfected with Hepatitis B And/Or C

Author(s) -

Christopher B. Hurt,

Sonia Napravnik,

Richard D. Moore,

Joseph J. Eron

Publication year - 2013

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2738

Subject(s) - raltegravir , medicine , tolerability , hazard ratio , ritonavir , hepatitis c , population , adverse effect , discontinuation , coinfection , gastroenterology , viral load , human immunodeficiency virus (hiv) , immunology , confidence interval , antiretroviral therapy , environmental health

Potential liver toxicity is an important consideration for antiretroviral selection among patients coinfected with HIV and viral hepatitis (B and/or C). We sought to describe the hepatic safety profile of raltegravir in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research